SIK3 and cancer: Although shSIK3 and SIK3 inhibitors decreased PD-L1 levels in cancer cells (Fig. 1e, f and Supplementary Fig. 1h, i), a SIK3 inhibitor, YKL-06-062, rendered the cancer cells resistant to the immune cells in the coculture condition (Supplementary Fig. 2k).